Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2006; 12(8): 1265-1269
Published online Feb 28, 2006. doi: 10.3748/wjg.v12.i8.1265
Published online Feb 28, 2006. doi: 10.3748/wjg.v12.i8.1265
Table 1 Comparison of clinical data of patients with chronic hepatitis C who received dual or triple therapy
| Triple therapygroup | Dual therapygroup | P value | |
| Demography | |||
| Male/Female | 24/26 | 38/14 | 0.0151 |
| Agea (yr) | 57±23 (27-69 ) | 53.8±9.8 (23-70) | NS2 |
| Body weighta (kg) | 60.5±9.8 (35-93) | 63.5±12.4 (35-93) | NS2 |
| BMIa (kg/m2) | 23.5±3.1 | 23.4±2.1 | NS2 |
| Naïve/Retreatment | 34/15 | 40/11 | NS1 |
| Biochemistry | |||
| HCV RNA (kcopy/mL) | 700 (100-1490) | 720 (110-2310) | NS2 |
| ALTa (U/L) | 95.6±61.1 | 97.4±59.8 | NS2 |
| Ferritina | 216.8±244.4 | 214±139.6 | NS2 |
| Serum zinca (μg/dL) | 73.3±20.3 | 69.8±17.2 | NS2 |
| Histopathology | |||
| F 0/1/2/3/4 | 3/12/23/10/1 | 1/20/15/13/1 | NS1 |
| A 1/2/3 | 26/20/2 | 20/24/5 | NS1 |
- Citation: Suzuki H, Takagi H, Sohara N, Kanda D, Kakizaki S, Sato K, Mori M. Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: A randomized controlled clinical trial. World J Gastroenterol 2006; 12(8): 1265-1269
- URL: https://www.wjgnet.com/1007-9327/full/v12/i8/1265.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i8.1265